Significant association seen for increasing continuous PRS313 and risk for contralateral disease after DCIS<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b>
\n<\/b><\/p>\n
THURSDAY, Oct. 9, 2025 (HealthDay News) — For women with in situ breast disease, the 313-single nucleotide polymorphism breast cancer polygenic risk score (PRS313<\/sub>) can predict the likelihood of developing future breast cancer, according to a study published online Oct. 1 in Cancer Epidemiology, Biomarkers & Prevention<\/em>.<\/p>\n Jasmine Timbres, from King’s College London, and colleagues evaluated whether the PRS313<\/sub> can predict the likelihood of developing ipsilateral or contralateral breast cancer after diagnosis of ductal carcinoma in situ (DCIS; 2,169 patients) or lobular carcinoma in situ (LCIS; 185 patients). Data were obtained from the Investigate the genetiCs of In situ Carcinoma of the ductaL subtypE<\/em> (ICICLE) and A study to investigate the Genetics of LobulAr Carcinoma In situ in EuRope<\/em> (GLACIER) studies; patients were followed for a median of 11 years.<\/p>\n The researchers observed a significant association between increasing continuous PRS313<\/sub> and the risk for contralateral disease following DCIS (hazard ratio, 1.30). A significant association was also seen between PRS313<\/sub> and ipsilateral disease after LCIS (hazard ratio, 2.16).<\/p>\n “The associations found in this study could be useful in helping women decide their treatment options after a diagnosis of DCIS or LCIS,” lead author Elinor J. Sawyer, M.B.B.S., Ph.D., also from King’s College London, said in a statement. “By looking at the full picture, rather than just how cells look under a microscope, we can give women more accurate information about their personal risk of recurrence. This could help them make more informed choices about their treatment options and what’s right for them.”<\/p>\n One author disclosed ties to the pharmaceutical industry.<\/p>\n